Melane Sampson, Author at BioTuesdays

Executive Moves

Healthcare Integrated Technologies appoints Anand Ijju as CTO

Healthcare Integrated Technologies (OTC PINK: HITC) announced the appointment of Anand Ijju as chief technology officer (CTO). Mr. Ijju brings extensive experience in scaling global technology ventures, complemented by...

April 10, 2025

Developments

ARPA-H grants Ginkgo and partners $29M to advance distributed manufacturing of medicines using grain

Ginkgo Bioworks (NYSE:DNA) announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H) and partners—Tritica Biosciences, US Pharmacopeia, On Demand Pharmaceuticals, and Isolere Bio by...

April 10, 2025

Developments

FDA grants three FTDs for Allogene’s ALLO-329

Allogene Therapeutics (NASDAQ:ALLO) announced that the FDA has granted three fast track designations (FTDs) for its ALLO-329, a next-generation dual-target CD19/CD70 allogeneic CAR T for the treatment of lupus...

April 8, 2025

Executive Moves

Telo appoints John Farlinger to BOD

Telo Genomics (TSXV:TELO) announced the appointment of John Farlinger to its board of directors (BOD) and will serve as chair of the company’s audit committee. With more than 30 years of experience in telecom...

April 4, 2025

Executive Moves

Leone Patterson joins Kalaris as BOD chair of audit committee

Kalaris Therapeutics (NASDAQ:KLRS) announced the appointment of Leone Patterson to its board of directors (BOD) as chair of the audit committee. Ms. Patterson brings extensive experience as a biotech executive and board...

April 4, 2025

Developments

TrillaMed and Profound partner to bring TULSA-PRO to Veterans and service members

Profound Medical (NASDAQ:PROF; TSX:PRN) and TrillaMed, a Service-Disabled Veteran-Owned Business (SDVOSB), have announced a partnership to support the federal deployment of TULSA-PRO—the MRI-guided, incision-free...

April 4, 2025

Developments

AC Immune reveals positive Phase 2 data from trial in early PD

AC Immune (NASDAQ:ACIU) announced additional interim safety and positive immunogenicity data from the Phase 2 VacSYn trial evaluating ACI-7104.056—its anti-alpha-synuclein (a-syn) active immunotherapy candidate—for the...

April 3, 2025

Executive Moves

Laurie Glimcher joins ReAlta’s BOD

Closely held ReAlta Life Sciences has appointed immunologist Laurie Glimcher, MD, to its board of directors (BOD), effective immediately. Dr. Glimcher, widely renown for her work in cancer research, brings more than 35...

April 1, 2025

Feature

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

MaaT Pharma (EURONEXT:MAAT) is at the forefront of developing the world’s first full-ecosystem approach to restoring microbiome symbiosis in oncology, improving cancer patient survival through innovative, fecal-derived...

April 1, 2025

Developments

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Kazia Therapeutics (NASDAQ:KZIA) announced it will receive $1 million for the sale of all intellectual property (IP) and trademark rights of Cantrixil to Vivesto (Nasdaq Stockholm:VIVE). Vivesto licensed the exclusive...

March 31, 2025

Author - Melane Sampson

Healthcare Integrated Technologies appoints Anand Ijju as CTO

ARPA-H grants Ginkgo and partners $29M to advance distributed manufacturing of medicines using grain

FDA grants three FTDs for Allogene’s ALLO-329

Telo appoints John Farlinger to BOD

Leone Patterson joins Kalaris as BOD chair of audit committee

TrillaMed and Profound partner to bring TULSA-PRO to Veterans and service members

AC Immune reveals positive Phase 2 data from trial in early PD

Laurie Glimcher joins ReAlta’s BOD

MaaT Pharma advancing next frontier biotherapeutics with microbiome-driven therapies

Kazia agrees to sell Cantrixil IP and trademark rights to Vivesto

Subscribe